Candel Therapeutics (CADL) Long-Term Debt Repayments (2024 - 2025)

Candel Therapeutics' (CADL) quarterly Long-Term Debt Repayments came in at -$4.2 million in Q4 2025, down 69.32% year-on-year from -$13.8 million in Q4 2024, and down 69.32% quarter-over-quarter from -$2.5 million in Q3 2025.

Candel Therapeutics (CADL) Long-Term Debt Repayments (2024 - 2025) Analysis & Trends

Candel Therapeutics has disclosed Long-Term Debt Repayments across 2 years of filings, most recently posting -$4.2 million for Q4 2025.

  • Long-Term Debt Repayments for Q4 2025 came in at -$4.2 million, down 69.32% year-over-year; the trailing twelve-month figure through Dec 2025 was -$11.7 million (down 27.99% YoY), and the FY2025 annual result was -$11.7 million, down 27.99% from the prior year.
  • Long-Term Debt Repayments came in at -$4.2 million for Q4 2025 at Candel Therapeutics, down from -$2.5 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of -$1.7 million in Q1 2024 to a low of -$4.2 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -21,671.00
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Candel Therapeutics 440.62 Mn 440.62 Mn - -4.23 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -4.23 Mn
Dec 31, 2025 -4.23 Mn
Sep 30, 2025 -2.50 Mn
Sep 30, 2025 -2.50 Mn
Jun 30, 2025 -2.50 Mn
Jun 30, 2025 -2.50 Mn
Mar 31, 2025 -2.50 Mn
Mar 31, 2025 -2.50 Mn
Dec 31, 2024 -2.50 Mn
Dec 31, 2024 -2.50 Mn
Sep 30, 2024 -2.50 Mn
Sep 30, 2024 -2.50 Mn
Jun 30, 2024 -2.50 Mn
Jun 30, 2024 -2.50 Mn
Mar 31, 2024 -1.67 Mn
Mar 31, 2024 -1.67 Mn